With the new financial year on the horizon, it could be a great time to deploy fresh capital into high-quality companies with long-term growth potential.
If you are lucky enough to have $5,000 to put to work in the share market, then read on.
That's because analysts have named several standout blue chip ASX 200 shares that they think have the potential to deliver big returns over the next 12 months.
Here's what they are recommending:
Image source: Getty Images
Aristocrat Leisure Ltd (ASX: ALL)
A global gaming leader, Aristocrat Leisure has successfully expanded from land-based gaming machines into high-growth digital and real money gaming segments. Its strong balance sheet, robust pipeline of new titles, and increasing exposure to recurring revenue make it one of the more compelling long-term growth stories on the ASX.
Bell Potter has a buy rating and $79.00 price target on its shares.
Cochlear Ltd (ASX: COH)
Another blue chip ASX 200 share to look at is Cochlear. It is the global leader in hearing implants — and demand for its products continues to rise as the world's population ages. With new products hitting the market this month, consistent investment in R&D, a dominant market share, and growing global adoption, Cochlear remains a high-quality stock to buy and hold.
UBS has a buy rating and $325.00 price target on Cochlear's shares.
James Hardie Industries plc (ASX: JHX)
Building products company James Hardie could be an ASX 200 blue chip share to buy according to brokers. It appears to be well placed for continued earnings growth thanks to the structural shift towards fibre cement from vinyl/timber in the US. This provides it with a multi-year runway for revenue and profit growth.
Bell Potter is bullish and has a buy rating and $63.00 price target on its shares.
ResMed Inc. (ASX: RMD)
ResMed could be a great ASX 200 blue chip share to buy in July. With its global leadership in sleep apnoea treatment, high-margin recurring revenue from devices and masks, and expanding digital ecosystem, ResMed arguably remains one of the best-positioned medtech plays on the ASX 200. And with a total addressable market estimated to be over 1 billion, it has a significant growth runway.
Ord Minnett has a buy rating and $46.50 price target on its shares.
Steadfast Group Ltd (ASX: SDF)
Finally, Steadfast is Australia's largest general insurance broker network. Its roll-up model and exposure to inflation-linked premiums make it resilient through economic cycles. For investors seeking dependable growth and income, this blue chip ASX 200 share could be a quiet achiever worth a closer look.
Macquarie thinks this is the case. It has an outperform rating and $6.80 price target on its shares.
